🇺🇸 SBP-101 in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 4
Most-reported reactions
- Chills — 1 report (25%)
- Pyrexia — 1 report (25%)
- Sepsis — 1 report (25%)
- Tremor — 1 report (25%)
Frequently asked questions
Is SBP-101 approved in United States?
SBP-101 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SBP-101 in United States?
Panbela Therapeutics, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.